Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)
Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –
Biogen gross margin
Gross margin is gross profit as a percentage of revenue.
Biogen's gross margin for the twelve months ending Sep 30, 2026 was 74.0%. For fiscal 2025 it was 75.7%, against 76.1% the year before. The highest annual figure on record is 91.5% in fiscal 2010.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 75.7% | −0.4 |
| FY2024 | Dec 31, 2024 | 76.1% | +1.9 |
| FY2023 | Dec 31, 2023 | 74.2% | −3.4 |
| FY2022 | Dec 31, 2022 | 77.6% | −3.2 |
| FY2021 | Dec 31, 2021 | 80.8% | −5.8 |
| FY2020 | Dec 31, 2020 | 86.6% | +0.2 |
| FY2019 | Dec 31, 2019 | 86.4% | −0.1 |
| FY2018 | Dec 31, 2018 | 86.5% | −0.2 |
| FY2017 | Dec 31, 2017 | 86.7% | −0.4 |
| FY2016 | Dec 31, 2016 | 87.1% | −1.4 |
| FY2015 | Dec 31, 2015 | 88.5% | +0.5 |
| FY2014 | Dec 31, 2014 | 87.9% | +0.3 |
| FY2013 | Dec 31, 2013 | 87.6% | −2.5 |
| FY2012 | Dec 31, 2012 | 90.1% | −0.6 |
| FY2011 | Dec 31, 2011 | 90.8% | −0.8 |
| FY2010 | Dec 31, 2010 | 91.5% | +0.2 |
| FY2009 | Dec 31, 2009 | 91.3% | +1.1 |
| FY2008 | Dec 31, 2008 | 90.2% | +0.8 |
| FY2007 | Dec 31, 2007 | 89.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 73.3% | −0.1 |
| Q2 FY2026 | Jun 30, 2026 | 71.6% | −5.5 |
| Q1 FY2026 | Mar 31, 2026 | 73.3% | −0.8 |
| Q4 FY2025 | Dec 31, 2025 | 78.3% | +2.0 |
| Q3 FY2025 | Sep 30, 2025 | 73.4% | −0.7 |
| Q2 FY2025 | Jun 30, 2025 | 77.1% | −0.7 |
| Q1 FY2025 | Mar 31, 2025 | 74.1% | −2.2 |
| Q4 FY2024 | Dec 31, 2024 | 76.2% | +2.1 |
| Q3 FY2024 | Sep 30, 2024 | 74.1% | +0.2 |
| Q2 FY2024 | Jun 30, 2024 | 77.8% | +2.0 |
| Q1 FY2024 | Mar 31, 2024 | 76.3% | +3.2 |
| Q4 FY2023 | Dec 31, 2023 | 74.1% | −3.5 |
| Q3 FY2023 | Sep 30, 2023 | 73.9% | −7.4 |
| Q2 FY2023 | Jun 30, 2023 | 75.9% | −5.4 |
| Q1 FY2023 | Mar 31, 2023 | 73.1% | +2.9 |
| Q4 FY2022 | Dec 31, 2022 | 77.6% | +1.7 |
| Q3 FY2022 | Sep 30, 2022 | 81.3% | −0.3 |
| Q2 FY2022 | Jun 30, 2022 | 81.3% | −2.1 |
| Q1 FY2022 | Mar 31, 2022 | 70.2% | −12.0 |
| Q4 FY2021 | Dec 31, 2021 | 75.9% | −6.9 |
| Q3 FY2021 | Sep 30, 2021 | 81.6% | −5.1 |
| Q2 FY2021 | Jun 30, 2021 | 83.4% | −5.4 |
| Q1 FY2021 | Mar 31, 2021 | 82.3% | −4.9 |
| Q4 FY2020 | Dec 31, 2020 | 82.8% | −5.0 |
| Q3 FY2020 | Sep 30, 2020 | 86.7% | −1.4 |
| Q2 FY2020 | Jun 30, 2020 | 88.8% | +2.0 |
| Q1 FY2020 | Mar 31, 2020 | 87.1% | +4.4 |
| Q4 FY2019 | Dec 31, 2019 | 87.8% | +1.7 |
| Q3 FY2019 | Sep 30, 2019 | 88.1% | +1.5 |
| Q2 FY2019 | Jun 30, 2019 | 86.8% | −0.6 |
| Q1 FY2019 | Mar 31, 2019 | 82.7% | −3.0 |
| Q4 FY2018 | Dec 31, 2018 | 86.1% | +1.5 |
| Q3 FY2018 | Sep 30, 2018 | 86.6% | −1.4 |
| Q2 FY2018 | Jun 30, 2018 | 87.5% | −0.6 |
| Q1 FY2018 | Mar 31, 2018 | 85.8% | −0.6 |
| Q4 FY2017 | Dec 31, 2017 | 84.6% | −2.2 |
| Q3 FY2017 | Sep 30, 2017 | 88.0% | – |
| Q2 FY2017 | Jun 30, 2017 | 88.1% | – |
| Q1 FY2017 | Mar 31, 2017 | 86.3% | – |
| Q4 FY2016 | Dec 31, 2016 | 86.8% | – |
See a number that looks wrong?